KW‑6356
Experimental drug candidate for Parkinson's disease, tested in humans so far only in small studies.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Pharmacology
Contents
DETAILED OVERVIEW
What is KW-6356?
KW-6356 (sipagladenant) is an experimental drug candidate being developed to treat Parkinson's disease. It is not approved in most regions, cannot be sold as a dietary supplement and is not meant for self-medication; its use in humans currently takes place within clinical trials.
In the movement-control area of the brain, a substance called adenosine puts a brake on the action of dopamine; the compound blocks one of the receptors for adenosine, that is, it releases the brake. In animal models it improved movement and strengthened the effect of levodopa, causing few involuntary movements, and improvement was also reported in people with early Parkinson's disease, but only a few small studies have been done in humans so far. Constipation and inflammation of the nose and throat were among the most common complaints, and long-term safety in humans is only partly known. Its effect may add up with other adenosine blockers, such as caffeine. Safety in pregnancy and breastfeeding has not been established.
Mechanism
Adenosine A2A antagonist / inverse agonist
Evidence
Human Phase 2 (Parkinson's, investigational)
Legal status
Investigational, unapproved drug
No anecdote collected yet.
Receptor profile
- Adenosine A2A receptorsStrong
- Striatal dopaminergic signaling (indirect)Moderate
- Adenosine A1 receptors (high A2A selectivity)Weak
Safety
Side effects, stop signs, contraindications
Side effects · 5
- Constipation, one of the most common complaints in early human trials
- Nasopharyngitis, also frequently reported in early trials
- Theoretical dyskinesia (involuntary movement) risk when combined with L-DOPA, though this appeared low in animal models
- Headache and nausea, as is common with the adenosine antagonist class
- Long-term safety in humans is only partly known: the compound is still investigational
Contraindications · 4
- Pregnancy and breastfeeding: safety not established, avoid
- Unapproved investigational drug: appropriate only within a clinical trial protocol under medical supervision
- Additive effect possible with other adenosine antagonists (e.g. caffeine, istradefylline)
- Effects may be prolonged due to the active metabolite and long half-life: interaction profile in humans not fully characterized
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A2A Receptor Antagonist/Inverse Agonist
Ohno Y, et al.
Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease
Maeda T, et al.
Anti-parkinsonian activity of the adenosine A2A receptor antagonist/inverse agonist KW-6356 as monotherapy in MPTP-treated common marmosets
Ohno Y, et al.
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets
Ohno Y, et al.
Safety, Tolerability, and Pharmacokinetics of the Novel Adenosine A2A Antagonist/Inverse Agonist KW-6356 Following Single and Multiple Oral Administration in Healthy Volunteers
Tayama T, et al.
FAQ
FAQ
KW-6356 (sipagladenant) is an experimental drug candidate still in development, being investigated for Parkinson's disease, with very little human data so far. In animal models and early-stage Parkinson's patients it improved motor function, and appears to boost the effect of L-DOPA without meaningfully raising the risk of unwanted movement side effects (dyskinesia). It has a long half-life, which in theory would allow once-daily dosing, but this is currently a research-stage compound, not an approved or marketed drug.
Telegram
Have a question about KW‑6356?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.
